Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2425-2431

  Kelly, Burnett ^a   Melhem, Murad ^a   Zhang, Jianhua ^b   Kasting, Gerald ^a   Li, Jinsong ^b   Krishnamoorthy, Mahesh ^c   Heffelfinger, Sue ^b   Rudich, Steven ^a   Desai, Pankaj ^a   Roy Chaudhury, Prabir ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c University of Cincinnati   (United States)

Author keywords

Anti proliferative therapy; Dialysis access stenosis; Haemodialysis vascular access dysfunction; Local drug delivery; Neointimal hyperplasia; Perivascular drug delivery

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; MACROGOL; PACLITAXEL; POLITEF; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; COST CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; GRAFT OCCLUSION; HEALTH CARE COST; HEALTH ECONOMICS; HEMODIALYSIS; IN VIVO STUDY; MORPHOMETRICS; NONHUMAN; POLITEF IMPLANT; PRIORITY JOURNAL; SWINE; TIME; VASCULAR ACCESS; ANIMAL; ARTERIOVENOUS SHUNT; COMPARATIVE STUDY; DISEASE MODEL; DRUG IMPLANT; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTERIOVENOUS SHUNT, SURGICAL; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; GRAFT OCCLUSION, VASCULAR; PACLITAXEL; SWINE; TREATMENT OUTCOME;

EID: 33750121616     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl250     Document Type: Article

References (33)

1. USRDS. United States Renal Data System; Annual Data Report. 2002
2. McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA. Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001; 60: 1164-1172
3. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996; 7: 523-535
4. Roy-Chaudhury P, Kelly BS, Zhang J et al. Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies. Blood Purif 2003; 21: 99-110
5. Beathard. The treatment of vascular access dysfunction: A nephrologists view and experience. ARRT 1994; 1: 131-147
6. Roy-Chaudhury P, Kelly BS, Melhem M et al. Vascular access in hemodialysis: Issues, management, and emerging concepts. Cardiol Clin 2005; 23: 9-273
7. Roy-Chaudhury P, Sukhatme V, Cheung A. Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol 2006; 60: 1164-1172
8. Roy-Chaudhury P, Kelly BS, Miller MA et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59: 2325-2334
9. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231
10. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000; 86: 879-884
11. Chaux A, Ruan XM, Fishbein MC et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998; 115: 604-612; discussion 12-4
12. Golomb G, Fishbein I, Banai S et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 1996; 125: 171-182
13. Hadeishi H, Mayberg MR, Seto M. Local application of calcium antagonists inhibits intimal hyperplasia after arterial injury. Neurosurgery 1994; 34: 114-121
14. Kaul S, Cercek B, Rengstrom J et al. Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: Role of nuclear factor-κB. J Am Coll Cardiol 2000; 35: 493-501
15. Muller DW, Golomb G, Gordon D, Levy RJ. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coron Artery Dis 1994; 5: 435-442
16. Kelly B, Melhem M, Desai P et al. Perivascular paclitaxel polymers reduce neointimal hyperplasia and venous stenosis in PTFE arteriovenous grafts: A possible solution for hemodialysis vascular access dysfunction. J Am Soc Nephrol 2004; 15: 25A
17. Melhem M, Kelly B, Zhang J et al. Development of a local perivascular paclitaxel delivery system for hemodialysis vascular access dysfunction: polymer preparation and in vitro activity. Blood Purification 2006; 24: 289-298
18. Kelly BS, Heffelfinger SC, Whiting JF et al. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int 2002; 62: 2272-2280
19. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809
20. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996; 94: 1655-1664
21. Shi Y, O'Brien JE Jr., Mannion JD et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997; 95: 2684-2693
22. Wallner K, Sharifi BG, Shah PK, Noguchi S, DeLeon H, Wilcox JN. Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol 2001; 37: 655-661
23. Roy-Chaudhury P, McKee L, Miller M et al. Adventitial fibroblasts contribute to venous neointimal hyperplasia in PTFE dialysis grafts. J Am Soc Nephrol 2001; 12: 301A
24. Misra S, Doherty MG, Woodrum D et al. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int 2005; 68: 2890-2900
25. Schwartz RS, Topol EJ, Serruys PW, Sangiorgi G, Holmes DR Jr. Artery size, neointima, and remodeling: Time for some standards. J Am Coll Cardiol 1998; 32: 2087-2094
26. Wilcox JN, Okamoto EI, Nakahara KI, Vinten-Johansen J. Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: A role for circulating myofibroblast precursors? Ann N Y Acad Sci 2001; 947: 68-90; Discussion 2
27. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V. Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res 2003; 40: 37-46
28. Wilcox JN, Waksman R, King SB, Scott NA. The role of the adventitia in the arterial response to angioplasty: The effect of intravascular radiation. Int J Radiat Oncol Biol Phys 1996; 36: 789-796
29. Labinaz M, Pels K, Hoffert C, Aggarwal S, O'Brien ER. Time course and importance of neoadventitial formation in arterial remodeling following balloon angioplasty of porcine coronary arteries. Cardiovasc Res 1999; 41: 255-266
30. Kwon HM, Sangiorgi G, Ritman EL et al. Adventitial vasa vasorum in balloon-injured coronary arteries: Visualization and quantitation by a microscopic three-dimensional computed tomography technique. J Am Coll Cardiol 1998; 32: 2072-2079
31. Serruys P, Sianos G, Den Heijer P. Paclitaxel in stent controlled elution study. Circulation 2004; 110: SIII, 385
32. Masaki T, Rathi R, Zentner G et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 2004; 66: 2061-2069
33. Schwartz RS. Neointima and arterial injury: Dogs, rats, pigs, and more. Lab Invest 1994; 71: 789-791